What is craniopharyngioma?
A craniopharyngioma is a rare, slow-growing tumour that develops at the base of the brain, close to the pituitary gland, the hypothalamus and the optic nerves. It is not a cancer in the usual sense: it does not spread to other parts of the body, and the WHO classes it as a low-grade (grade 1) tumour.
Its position makes it a serious condition, however. The nearby structures control vision, growth, puberty, thirst, appetite, body temperature, sleep and the body’s stress hormones. Both the tumour and its treatment can damage them.
Craniopharyngiomas are thought to grow from left-over cells of Rathke’s pouch, a structure in the developing embryo that forms part of the pituitary gland. They often contain fluid-filled cysts as well as solid tumour, and many contain calcium deposits.
Most people survive for many years after treatment. The main challenge is long-term quality of life, because many survivors need lifelong hormone replacement and some have problems with vision, weight, memory or behaviour.
1. How common is it?
Craniopharyngioma affects about 1-2 people per million each year. It accounts for about 1-4% of brain tumours in children and is the most common non-neuroepithelial tumour of the brain in childhood.
| Feature | Details |
|---|---|
| Age | Two peaks: children aged 5-14 and adults aged about 45-70. About a third to a half of cases occur in children |
| Sex | Affects males and females equally |
| Location | Above the pituitary gland (suprasellar), often reaching into the third ventricle; sometimes inside the pituitary fossa (sella) |
| Behaviour | Slow-growing; does not spread to other organs, but often comes back after incomplete removal |
2. Causes and types
Craniopharyngioma is not inherited and is not caused by anything a person or parent did. The tumours are driven by gene changes that arise in the tumour cells alone.
In the WHO Classification of Tumours of the Central Nervous System, 5th edition (CNS5, 2021), the two forms of craniopharyngioma are recognised as separate tumour types rather than subtypes of one tumour. They differ in age group, appearance, genetics and DNA methylation profile. Both are graded as CNS WHO grade 1.
| Feature | Adamantinomatous craniopharyngioma (ACP) | Papillary craniopharyngioma (PCP) |
|---|---|---|
| How common | About 9 in 10 cases overall; almost all childhood cases | About 1 in 10 cases overall; about 1 in 3 to 1 in 5 adult cases |
| Age | Children and adults (peaks at 5-15 and 45-60) | Almost only adults, mainly aged 40-60 |
| Driver mutation | CTNNB1 (beta-catenin), found in most cases; activates the WNT signalling pathway | BRAF V600E, found in more than 90% of cases; activates the MAPK pathway |
| Appearance | Mostly cystic, with calcium deposits in about 9 in 10 | Mostly solid, rarely calcified |
| Typical position | Above and inside the sella, often stuck to the hypothalamus | Often within the third ventricle |
| Targeted treatment | None yet standard; studied in trials | BRAF and MEK inhibitors can shrink the tumour |
3. How does it look?
3.1 On the body
A craniopharyngioma cannot be seen from the outside. Its effects, however, can often be noticed:
- Short stature: a child grows more slowly than their friends and falls behind on growth charts.
- Delayed or absent puberty, or early puberty in a few children.
- Weight gain, sometimes rapid, with a constant feeling of hunger.
- Changes in the eyes: a squint, difficulty seeing to the side, or bumping into things. The eye doctor may see a pale optic nerve.
- Signs of raised pressure in the head in a child, such as vomiting and drowsiness.
3.2 On scans
MRI of the brain is the main test. A CT scan shows calcium deposits particularly well, which helps to tell a craniopharyngioma apart from other tumours in this area.
| Feature | Typical appearance |
|---|---|
| Cysts (mainly ACP) | Fluid-filled spaces that often look bright on T1-weighted MRI because of protein and cholesterol |
| Solid parts | Enhance (light up) after contrast dye |
| Calcium | Bright white on CT; present in most ACPs, rare in PCPs |
| PCP | Usually a solid or mixed tumour in the third ventricle without calcium |
| Effects on nearby structures | Pushes on the optic chiasm, flattens the pituitary gland, may press on the hypothalamus and block the flow of cerebrospinal fluid (hydrocephalus) |
The typical ACP combination of cysts, calcium and a solid part that lights up with contrast is often called the “90% rule”. About 9 in 10 such tumours are cystic, 9 in 10 are calcified and 9 in 10 enhance with contrast.
3.3 During surgery and under the microscope
At surgery, ACP cysts often contain a thick, dark, greenish-brown fluid with glittering cholesterol crystals. This is often described as looking like “machinery oil”.
| Feature | ACP | PCP |
|---|---|---|
| Microscope | Cell layers with a palisaded edge, loose “stellate reticulum”, nodules of “wet keratin” and calcium | Sheets of squamous cells around blood vessels, forming papillae; no wet keratin |
| Special stains | Beta-catenin in the cell nucleus | BRAF V600E protein (VE1 stain) |
| Effect on the brain | Finger-like projections into nearby tissue with marked scarring and inflammation, so it sticks firmly to the hypothalamus | Usually a clearer border with brain tissue |
4. Symptoms
Symptoms usually develop slowly over months or years, and are often present for 1-2 years before diagnosis. They arise from pressure on the brain, the optic nerves and the pituitary and hypothalamus.
| Group | Symptoms |
|---|---|
| Raised pressure in the head | Headache (the most common symptom), especially in the morning, nausea and vomiting, drowsiness |
| Vision | Loss of side vision in both eyes (bitemporal hemianopia), blurred or reduced vision, double vision or a squint |
| Pituitary hormone deficiency | Slow growth, delayed puberty, missed periods, low sex drive, tiredness, feeling cold, dry skin |
| Lack of vasopressin | Passing large amounts of urine and constant thirst (arginine vasopressin deficiency, formerly called diabetes insipidus) |
| Hypothalamus | Weight gain and excessive hunger, sleepiness during the day, poor temperature control, changes in behaviour or memory |
In children, slow growth and headaches are common first signs. In adults, problems with vision and hormone deficiencies, such as loss of periods or erectile dysfunction, are more typical.
When to see a doctor
See a doctor if a child grows much more slowly than expected or shows no signs of puberty at the usual age. Also seek medical advice for persistent morning headaches with vomiting, any change in vision, or new excessive thirst and urination.
Seek urgent care for a sudden severe headache, sudden loss of vision, confusion or extreme drowsiness.
5. Diagnosis
Craniopharyngioma is diagnosed with brain imaging, hormone tests and eye tests. The diagnosis is confirmed by examining tissue removed at surgery or biopsy.
| Test | Purpose |
|---|---|
| MRI of the brain | Shows the size and extent of the tumour, the cysts and the involvement of the hypothalamus and optic nerves |
| CT scan | Shows calcium deposits; helps surgical planning |
| Hormone blood tests | Check cortisol, thyroid hormones, growth hormone markers (IGF-1), sex hormones and prolactin |
| Water balance tests | Blood and urine sodium and concentration to look for vasopressin deficiency |
| Eye examination | Visual acuity, visual fields and the appearance of the optic nerves |
| Growth and weight measurements | Height, weight and growth rate in children |
| Neuropsychological assessment | Memory, attention and behaviour, ideally before treatment |
| Tissue examination | Confirms the type; BRAF V600E testing is done on suspected papillary tumours |
Other conditions in this area include pituitary adenoma, Rathke’s cleft cyst, germ cell tumours, optic pathway glioma and Langerhans cell histiocytosis. Calcium deposits and cysts favour craniopharyngioma, but tissue is usually needed for certainty.
Before any surgery, missing cortisol and thyroid hormones must be replaced. An untreated lack of cortisol can be life-threatening during an operation.
6. Hypothalamic involvement
How far the tumour involves the hypothalamus is the most important factor in planning treatment. Surgeons and radiologists use grading systems, such as the Paris (Puget) grading.
| Grade | Meaning |
|---|---|
| Grade 0 | No involvement of the hypothalamus |
| Grade 1 | The tumour pushes or lifts the hypothalamus, which is still visible |
| Grade 2 | The tumour has grown into the hypothalamus, which can no longer be seen separately |
When the hypothalamus is involved (grade 2), trying to remove the whole tumour carries a high risk of permanent hypothalamic damage. In this situation, a hypothalamus-sparing approach is generally preferred.
7. Treatment
Treatment should be planned by a specialist team, which includes neurosurgeons, endocrinologists, radiation oncologists, eye specialists and, for children, paediatric oncologists. The aim is to control the tumour while protecting vision, hormone function and the hypothalamus.
7.1 Main treatment strategies
| Strategy | When it is used | Advantages | Disadvantages |
|---|---|---|---|
| Complete (gross total) removal | Tumour does not involve the hypothalamus and can be removed safely | Often no radiotherapy needed; low chance of regrowth | Risk of hormone deficiency, vision loss and hypothalamic damage if attempted when the tumour is stuck to the hypothalamus |
| Limited surgery plus radiotherapy | Tumour involves the hypothalamus or is stuck to vital structures | Tumour control similar to complete removal, with less damage to the hypothalamus | Side effects of radiotherapy; needs careful long-term follow-up |
| Cyst drainage | Large cysts causing pressure | Quick relief, often through a small catheter and an Ommaya reservoir placed under the scalp | Cysts can refill; usually combined with other treatment |
| Targeted drugs (BRAF/MEK inhibitors) | Papillary tumours with BRAF V600E | Can shrink the tumour dramatically, sometimes avoiding major surgery | Long-term results still being studied; side effects such as rash and fever |
7.2 Surgery
Surgery may be done through the nose (endoscopic endonasal surgery) or through an opening in the skull (craniotomy). The best route depends on where the tumour lies.
Without further treatment, a tumour that is only partly removed comes back in about half or more of people. After complete removal, regrowth is less common, but it can still happen.
Surgery also relieves raised pressure in the head. If the tumour blocks the flow of fluid in the brain, a shunt or other drainage may be needed.
7.3 Radiotherapy and proton therapy
Radiotherapy is given after limited surgery or when the tumour grows back. The usual dose is about 54 Gy, given in small daily doses over about 6 weeks. Modern techniques include intensity-modulated radiotherapy (IMRT) and proton beam therapy.
Proton therapy delivers less radiation to the healthy brain around the tumour. This is particularly important for children, to protect memory, learning and hormone function.
In a phase 2 study at St Jude Children’s Research Hospital, 94 children and young people were treated with limited surgery and proton therapy. After 3 years, 96.8% were free of tumour progression and all were alive. Serious problems such as tissue damage, narrowing of blood vessels (vasculopathy) and permanent neurological deficits occurred in only a few per cent.
Cysts can swell temporarily during or after radiotherapy. Scans are therefore repeated during treatment, and the cyst may need to be drained.
Late effects of radiotherapy include hormone deficiencies, effects on memory and learning, narrowing of blood vessels, and a small risk of a second tumour many years later.
7.4 Treatment of cysts
Mainly cystic ACPs can sometimes be treated by injecting drugs directly into the cyst through an Ommaya reservoir. Interferon-alpha is the drug most often used in this way. It can shrink the cyst and delay surgery or radiotherapy, particularly in young children.
7.5 BRAF and MEK inhibitors for papillary craniopharyngioma
Because more than 90% of papillary craniopharyngiomas carry the BRAF V600E mutation, drugs that block BRAF and MEK can be very effective.
In the US Alliance phase 2 trial, 16 adults with papillary craniopharyngioma who had not had radiotherapy received vemurafenib plus cobimetinib. Fifteen (94%) had a partial response or better, and the median reduction in tumour volume was 91%. Progression-free survival was 87% at 1 year and 58% at 2 years, and some tumours grew again after treatment stopped.
Dabrafenib plus trametinib has shown similar effects in reports of individual patients and small series. These drugs may be used before surgery or radiotherapy, or for tumours that come back. They are not formally licensed for craniopharyngioma, so they are given in trials or off-label.
Common side effects include rash, sensitivity to sunlight, fever, joint pain, tiredness and raised blood sugar or muscle enzymes. Regular skin and eye checks are needed.
For ACP, there is no established targeted drug. Trials are testing drugs that block inflammatory signals, such as IL-6 (tocilizumab), and other pathways, including MEK inhibitors and immunotherapy.
8. Hormone problems and hypothalamic obesity
8.1 Endocrine deficits
Most people have at least one pituitary hormone deficiency after treatment, and many have several. Hormone replacement is usually needed for life.
| Hormone deficiency | Effect | Replacement |
|---|---|---|
| Growth hormone | Poor growth in children; tiredness, more body fat and weaker bones in adults | Daily or weekly growth hormone injections |
| ACTH (cortisol) | Tiredness, low blood pressure, low blood sugar; adrenal crisis during illness can be life-threatening | Hydrocortisone tablets, with extra doses during illness (“sick day rules”), an emergency injection kit and a steroid card |
| TSH (thyroid) | Tiredness, weight gain, feeling cold, slow growth | Levothyroxine tablets |
| LH and FSH (sex hormones) | Delayed or absent puberty, loss of periods, low sex drive, reduced fertility | Testosterone or oestrogen; fertility treatment if desired |
| Vasopressin (AVP) | Large amounts of dilute urine and thirst | Desmopressin tablets, nasal spray or melts, with careful monitoring of sodium |
Some people also lose their normal sense of thirst. Their fluid intake and sodium levels need especially careful management.
8.2 Hypothalamic obesity
Damage to the hypothalamus can disturb the brain’s control of hunger, fullness and energy use. This causes hypothalamic obesity, which affects up to half of people treated for craniopharyngioma, particularly when the hypothalamus was involved.
Weight gain often begins soon after surgery and may be rapid despite great effort with diet and exercise. It is linked with type 2 diabetes, high blood pressure, sleep apnoea, liver problems and heart disease, and it has a major effect on quality of life.
Management includes early advice from a dietitian, a structured eating plan, regular physical activity and good sleep. Hormone deficiencies also need to be fully treated.
Medication is increasingly used. GLP-1 receptor agonists can help some people.
Setmelanotide, which acts on the melanocortin-4 receptor in the hypothalamus, reduced body mass index by 16.5% compared with placebo in the phase 3 TRANSCEND trial. It was approved in the US in 2026 for acquired hypothalamic obesity in people aged 4 years and older. Bariatric surgery is an option for selected adults.
The best prevention is to avoid hypothalamic injury where possible. This is the reason for hypothalamus-sparing surgery.
9. Prognosis
Survival after craniopharyngioma is high. In large series, about 9 in 10 children are alive 10 years after diagnosis.
- Survival is similar after complete removal and after limited surgery with radiotherapy.
- Without radiotherapy, a tumour that was only partly removed often grows back, usually within a few years.
- Hypothalamic involvement is the main predictor of long-term problems, including obesity, tiredness, poor memory and behaviour difficulties.
- Lifelong hormone deficiency is common. People with craniopharyngioma have a higher long-term risk of death than the general population, mainly from heart and blood vessel disease, adrenal crisis and problems with water balance.
- Survival in adults is generally a little lower than in children, partly because of other health problems.
10. Follow-up and living with craniopharyngioma
10.1 Follow-up
MRI scans are usually done every 3-6 months at first and then less often, for many years. Regular reviews by an endocrinologist and an eye specialist are needed for life. Children are also followed for growth, puberty, school performance and wellbeing, with a planned move to adult services.
10.2 Everyday life
- Always carry a steroid emergency card if you take hydrocortisone, and know how to increase your dose during illness or give an emergency injection.
- Learn the signs of high or low sodium, such as headache, confusion, unusual tiredness or excessive thirst, if you take desmopressin.
- Wear a medical alert bracelet or carry information about your condition.
- School and work adjustments can help with tiredness, memory problems or vision loss.
- Regular exercise, a healthy eating plan and good sleep habits help with weight and energy.
- Psychological support is valuable for people and families coping with changes in behaviour, weight or self-esteem.
- Patient organisations such as the Pituitary Foundation offer information, helplines and support groups.
Resources
- Louis, D.N. et al. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- Muller, H.L. et al. (2019) ‘Craniopharyngioma’, Nature Reviews Disease Primers, 5(1), p. 75.
- Bunin, G.R. et al. (1998) ‘The descriptive epidemiology of craniopharyngioma’, Journal of Neurosurgery, 89(4), pp. 547-551.
- Sekine, S. et al. (2002) ‘Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations’, American Journal of Pathology, 161(6), pp. 1997-2001.
- Brastianos, P.K. et al. (2014) ‘Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas’, Nature Genetics, 46(2), pp. 161-165.
- Karavitaki, N. et al. (2005) ‘Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up’, Clinical Endocrinology, 62(4), pp. 397-409.
- Merchant, T.E. et al. (2023) ‘Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study’, Lancet Oncology, 24(5), pp. 523-534.
- Brastianos, P.K. et al. (2023) ‘BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas’, New England Journal of Medicine, 389(2), pp. 118-126.
- Stec, N.E., Barker, F.G. and Brastianos, P.K. (2025) ‘Targeted treatment for craniopharyngioma’, Journal of Neuro-Oncology, 172(3), pp. 503-513.
- Muller, H.L. et al. (2022) ‘Hypothalamic syndrome’, Nature Reviews Disease Primers, 8(1), p. 24.
- Roth, C.L. et al. (2024) ‘Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial’, Lancet Diabetes & Endocrinology, 12(6), pp. 380-389.
- Miller, J.L. et al. (2026) ‘Setmelanotide for the treatment of acquired hypothalamic obesity’, New England Journal of Medicine, 395(2), pp. 138-150.
- Pituitary Foundation (2026) Craniopharyngioma. Available at: https://www.pituitary.org.uk/information/pituitary-conditions/craniopharyngioma/ (Accessed: October 2026).
Prepared by the editorial team, October 2026.